Orbsen Therapeutics

Executive Summary

Orbsen Therapeutics is a private Irish cell and gene therapy company founded in 2012 and based in Galway. The company is developing proprietary therapies targeting diabetic foot ulcers, acute respiratory distress syndrome (ARDS), and diabetic kidney disease. With a focus on addressing significant unmet medical needs, Orbsen leverages its platform to create treatments for chronic and acute conditions. While the company has not disclosed specific financials or pipeline stages, its niche focus in cell therapy for diabetes complications and ARDS positions it in high-demand areas. Orbsen remains in early development stages, with no public information on clinical trial progress or partnerships. The company's potential lies in advancing its preclinical or early clinical programs toward proof-of-concept data, which could attract strategic interest or funding.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Trial for ARDS Therapy30% success
• Q2 2026Preclinical Data Release for Diabetic Kidney Disease Program40% success
• Q1 2027Partnership or Licensing Deal for Diabetic Foot Ulcer Candidate20% success